A 12 week prospective clinical evidence of empagliflozin efficacy in uncontrolled type 2 diabetes mellitus treated with metformin and a sulfonylurea

Simple item page
dc.contributor.authorPuli, Keerthanaen_US
dc.contributor.authorVanjari, Nikhil Kumaren_US
dc.date.accessioned2020-04-23T07:59:27Z
dc.date.available2020-04-23T07:59:27Z
dc.date.issued2019-12
dc.description.abstractBackground: The main aim of the study is to evaluate the efficacy of empagliflozin 10 mg once daily over 12 weeks as add-on therapy to metformin plus sulfonylurea in patients with type 2 diabetes mellitus with inadequate glycemic control.Methods: It is a prospective, observational, study conducted in patients of Sri Badhrakali Diabetic Center located in Warangal, Telangana, India. The efficacy of empagliflozin 10 mg was assessed by measuring the change in the glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), body mass index (BMI) at the baseline and 12 weeks, systolic blood pressure (SBP) and diastolic blood pressure (DBP) at the baseline and after 24 hours of treatment.Results: In the present study, the addition of empagliflozin to metformin and Sulfonylurea therapy for 12 weeks provided 0.87 % reduction in HbA1c. The mean changes of FPG from baseline to 12-week is -26 mg/dl. At 24 hours empagliflozin significantly reduced blood pressure with mean changes of SBP and DBP -4.147 and -1.526 mmHg respectively. The mean changes in BMI from baseline to week 12 is -0.638 kg/m2.Conclusions: Empagliflozin 10 mg provided ancillary reduction in HbA1c outside of metformin and sulfonylurea. Controlled body weight, HbA1c, blood pressure decreases diabetes progression, decreased risk of diabetic complications and reduced risk for cardiovascular disorders.en_US
dc.identifier.affiliationsDepartment of Clinical Pharmacy, Vaageswari College of Pharmacy, Karimnagar, Telangana, Indiaen_US
dc.identifier.citationPuli Keerthana, Vanjari Nikhil Kumar. A 12 week prospective clinical evidence of empagliflozin efficacy in uncontrolled type 2 diabetes mellitus treated with metformin and a sulfonylurea. International Journal of Basic & Clinical Pharmacology. 2019 Dec; 8(12): 2639-2644en_US
dc.identifier.issn2319-2003
dc.identifier.issn2279-0780
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/200440
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber12en_US
dc.relation.volume8en_US
dc.source.urihttps://dx.doi.org/10.18203/2319-2003.ijbcp20195271en_US
dc.subjectType 2 diabetes mellitusen_US
dc.subjectHbA1cen_US
dc.subjectFPGen_US
dc.subjectBMIen_US
dc.subjectSodium glucose co-transporter 2 Inhibitoren_US
dc.subjectSulfonylureaen_US
dc.subjectMetforminen_US
dc.subjectDBPen_US
dc.subjectSBPen_US
dc.titleA 12 week prospective clinical evidence of empagliflozin efficacy in uncontrolled type 2 diabetes mellitus treated with metformin and a sulfonylureaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijbcp2019v8n12p2639.pdf
Size:
460.99 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Basic & Clinical Pharmacology